TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
173 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633
Recruiting
Phase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.32 enrolled9 locationsNCT06680037
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.500 enrolled85 locationsNCT06433752
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.16 enrolled5 locationsNCT06143514